+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06916585

Phase II Study of Injectable AS1501 for Treating Acute-on-Chronic Liver Failure in Adults Aged 18 to 75

Led by Shenzhen Third People's Hospital · Updated on 2026-07-17

96

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase II clinical trial to evaluate the safety and efficacy of the injectable drug AS1501 in patients with acute-on-chronic liver failure ACLF. The study includes two stages Phase IIa, which is a single-arm sentinel design focusing on two dose groups, and Phase IIb, a randomized, double-blind, placebo-controlled phase to further assess treatment effects. The trial aims to determine the appropriate dosing and safety profile of AS1501 in this patient population who are in early or intermediate stages of ACLF and are not candidates for liver transplantation. In Phase IIa, participants receive a single intravenous dose of AS1501 at either 0.5 mgkg or 1 mgkg, with the first two subjects serving as sentinels for safety monitoring. Following a 20-day washout period without severe adverse events, subjects enter a multiple-dose phase receiving weekly doses for four consecutive weeks. Dose adjustments may be made based on adverse events, and additional subjects may be enrolled to maintain group sizes. Phase IIb will randomize 72 ACLF subjects to receive AS1501 at the recommended dose or placebo, with dosing schedules finalized after Phase IIa results. Participants undergo regular monitoring throughout the study, including safety assessments for adverse events and serious adverse events over 42 days. The study involves careful evaluation of liver function, infection status, and other medical conditions to ensure safety. Participants must agree to effective contraception and complete the trial protocol. The trial is sponsored by Shenzhen Third Peoples Hospital and is expected to run from June 2026 to December 2027.

CONDITIONS

Brief Title

Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients

Research Team

Q

Qiang Sun

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here